KRN-330

DB19075InvestigationalProtein Based Therapies

Anti-a33 fully-human monoclonal antibody is under investigation in clinical trial NCT00838578 (Phase I/II Study of KRN330 Plus Irinotecan in Patients With Metastatic Colorectal Cancer).

Mechanism: Pharmacologically active on Cell surface A33 antigen
Curator reviewed
Also known as: ANTI-A33 FULLY-HUMAN MONOCLONAL ANTIBODY · HUMAN MONOCLONAL ANTIBODY TO COLON CANCER ANTIGEN A33
Code names: KRN-330

Resolves to

Compound

UNIIA64J777I28

Targets

Q99795GPA33

What you can answer from here — as of June 15, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

2Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with KRN-330, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account